



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

27 April 2021

COVID-19 vaccination status as of 0:00 today (cumulative since 26 February 2021)

	Total	City							
		Seoul	Busan	Daegu	Incheon	Gwangju	Daejeon	Ulsan	Sejong
New (1st dose)	141,937	23,323	7,696	5,905	6,286	3,931	4,176	2,084	707
New (1st dose)	21,598	3,411	898	514	1,005	933	492	965	200
Total (1st)	2,409,975	379,120	146,543	101,271	119,664	80,793	66,001	43,623	12,007
Total (2nd)	126,503	21,910	6,746	4,568	12,142	3,915	4,813	4,957	1,424
	Total	Province							
		Gyeonggi	Gangwon	Chung-buk	Chung-nam	Jeon-buk	Jeon-nam	Gyeong-buk	Gyeong-nam
New (1st dose)	30,764	4,402	5,282	5,191	11,439	9,208	10,127	9,631	1,785
New (1st dose)	2,715	1,640	1,492	1,521	1,566	1,509	393	1,776	568
Total (1st)	515,292	88,018	90,938	122,644	122,725	142,507	162,083	186,127	30,619
Total (2nd)	19,437	7,062	7,453	6,097	6,423	5,350	3,326	7,232	3,648

※ Figures subject to correction recording update

Adverse events following COVID-19 vaccination reported as of 0:00 today (cumulative since 26 February 2021)

		Vaccinated (cumulative)	Total	%	General ¹⁾	Anaphylaxis suspected ²⁾	Severe suspected ³⁾	Deaths
Total	New	2,536,478	546	0.56	538	4	2	2
	Total		14,155		13,901	147	45	62
AstraZeneca	New	1,370,849	411	0.91	406	3	2	-
	Total		12,508		12,315	120	33	40
Pfizer	New	1,165,629	135	0.14	132	1	-	2
	Total		1,647		1,586	27	12	22

¹⁾ Mild cases such as headache, fever, nausea, vomiting, etc.

²⁾ Anaphylactoid reaction and anaphylactic shock suspected cases reported by healthcare institutions; Anaphylactoid reaction refers to occurrence of symptoms such as shortness of breath, rashes, etc. within 2 hours of vaccination and differs from anaphylaxis

³⁾ Includes convulsion and other nervous system response and ICU admitted cases

※ Based on the patient's condition at the time of initial report (general, anaphylaxis suspected, severe suspected, death)

※ Cases reported as suspected cases of AEFI; causal association not yet determined; investigation for assessment of causal association to take place for deaths or anaphylaxis cases



KDCA

Korea Disease Control and Prevention Agency

Updates on COVID-19 in Republic of Korea

27 April 2021

Confirmed cases by gender and age group

		New cases (%)	Total cases (%)	Incidence rate* (per 100,000)
Total		512 (100)	119,898 (100)	231.25
Sex	Male	270 (52.73)	59,689 (49.78)	230.79
	Female	242 (47.27)	60,209 (50.22)	231.71
Age	80 or above	9 (1.76)	5,250 (4.38)	276.43
	70-79	27 (5.27)	8,677 (7.24)	240.55
	60-69	80 (15.63)	18,441 (15.38)	290.67
	50-59	101 (19.73)	22,217 (18.53)	256.34
	40-49	79 (15.43)	17,733 (14.79)	211.38
	30-39	73 (14.26)	16,123 (13.45)	228.85
	20-29	81 (15.82)	17,891 (14.92)	262.86
	10-19	36 (7.03)	8,393 (7.00)	169.88
0-9	26 (5.08)	5,173 (4.31)	124.69	

* Total (cumulative) number of cases reported since January 2020 by sex and age / Population by sex and age (based on resident registration data of the Ministry of the Interior as of January 2020)

※ Figures subject to correction based on findings from epidemiological investigations

Deaths and severe/critical patients by gender and age group

		New deaths (%)	Total deaths (%)	Case fatality rate (%)	Severe/critical (%)
Total		3 (100)	1,820 (100)	1.52	156 (100)
Sex	Male	1 (33.33)	906 (49.78)	1.52	100 (64.10)
	Female	2 (66.67)	914 (50.22)	1.52	56 (35.90)
Age	80 or above	3 (100)	1,001 (55.00)	19.07	35 (22.44)
	70-79	0 (0.00)	521 (28.63)	6.00	53 (33.97)
	60-69	0 (0.00)	212 (11.65)	1.15	46 (29.49)
	50-59	0 (0.00)	62 (3.41)	0.28	14 (8.97)
	40-49	0 (0.00)	14 (0.77)	0.08	6 (3.85)
	30-39	0 (0.00)	7 (0.38)	0.04	1 (0.64)
	20-29	0 (0.00)	3 (0.16)	0.02	1 (0.64)
	10-19	0 (0.00)	0 (0.00)	0.00	0 (0.00)
0-9	0 (0.00)	0 (0.00)	0.00	0 (0.00)	

* Case fatality rate (CFR) (%) = Number of deaths / Number of confirmed cases x 100

※ Figures subject to correction based on findings from epidemiological investigations

AGE DISTRIBUTION OF SEVERE/CRITICAL CASES

	4.14.	4.15.	4.16.	4.17.	4.18.	4.19.	4.20.	4.21.	4.22.	4.23.	4.24.	4.25.	4.26.	4.27.
Total	100	99	111	108	102	99	109	116	125	127	136	136	132	156

* Severe/Critical: COVID-19 patients in isolation being treated with high flow oxygen therapy, mechanical ventilator, ECMO (Extracorporeal Membrane Oxygenation), CRRT (Continuous Renal Replacement Therapy)